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Asian men. The extent of causality in these observations is yet to be determined, 
with further prospective cohort studies needed. Nevertheless, these findings high-
light the importance of properly managing patients with these risk factors to 
minimise the risk of fractures.
Muscular-skeletal DisorDers – cost studies
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Objectives: Currently in China, celecoxib is prescribed to patients with gastro-
intestinal bleeding or perforation history. The aim of this study was to model the 
effect of expanding access to all osteoarthritis (OA) patients in China. MethOds: 
We created a one-year budget impact model from a payer perspective comparing 
two scenarios. The first scenario (A) restricts the use of celecoxib to only patients 
with gastrointestinal bleeding or perforation history while the second scenario 
(B) does not restrict usage. In (A), patients were prescribed either diclofenac or 
celecoxib, but those prescribed celecoxib were only dispensed celecoxib if they 
had gastrointestinal bleeding or perforation history. Those prescribed celecoxib 
but not fitting the criteria were dispensed diclofenac. In (B), all prescriptions were 
dispensed as written. For both scenarios, celecoxib and diclofenac prescriptions 
were written 16.2% and 8% of the time, respectively. Patients with gastrointestinal 
bleeding or perforation history made up 5.58% of the OA population. Celecoxib was 
associated with a 20% copay while diclofenac did not have a copay. The base case 
scenario assumes 13,333 patients. Results: Going from (A) to (B), the total cost of 
celecoxib increased ¥2,679,866 (94.42%) while the total cost of diclofenac decreased 
¥1,817,170 (65.66%). The incremental total cost of drugs increased ¥862,697 (29.48%). 
The impact on a payer’s plans for the year was only due to drug costs since the 
cost to administer prior authorization was not considered. The per member per 
month increased ¥0.07 from ¥0.24 to ¥0.32. cOnclusiOns: The expanded access 
scenario (B) resulted in slightly higher drug costs to the payer, which may be accept-
able under most thresholds. Patient outcomes should also be considered to fully 
understand the impact of removing the gastrointestinal bleeding and perforation 
history stipulation.
PMs9
Prescribing Pattern anD cost analysis on (DMarD’s) Disease 
MoDifying anti rheuMatoiD Drugs in rheuMatoiD arthritis Patients 
of a tertiary care teaching hosPital in south inDia – a cross 
sectional stuDy
Tummeti  V.V.V.
Raghavendra Institute of Pharmaceutical Education & Research, Anantapur, India
Objectives: To study the current prescription pattern and to analyze the cost 
of the treatment prescribed to RA patients referred to orthopedics OPD in a ter-
tiary care teaching hospital of South India. MethOds: The study protocol was 
approved by the institutional ethics committee. Patients attending Orthopedic OPD 
for existing RA disease were recruited as per inclusion criteria. Written informed 
consent was sought. Total 100 consecutive rheumatoid arthritis patients (fulfilling 
the American College of Rheumatology Criteria 1987) were recruited during study 
period. Study Design: Cross-sectional study. Study Duration: 06 Months (From July 
1st to December 31st 2014) Study Site: Department of Orthopedics, Government 
Medical College and Hospital, Anantapuramu, Andhra Pradesh, India. Results: 
Majority of patients (67%) in the study population were on combination of two 
DMARDs. Most frequently prescribed two DMARDs combination was methotrexate 
and hydroxychloroquine (64%). Average total cost per prescription was found to be 
763.39, while average hospital and out of pocket expense were 281.12 and 482.88 
respectively. cOnclusiOns: The drug use pattern in RA was found to be DMARDs 
based and majority of the cost was borne by the patient. The total increase in cost 
was due to administration of drugs to treat the adverse drug reaction. Prospective 
studies in a larger number of patients are needed to assess the utility of prescription 
audit and cost analysis of drugs used in RA.
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Objectives: To estimate the societal costs of cycling accidents in Tasmania, 
Australia. MethOds: Between July 2011 and March 2012, 136 regular cyclists 
completed a telephone-based questionnaire. Information collected included 
demographics, cycling habits and details of major (requiring medical treatment 
or days off work) and minor (not requiring medical treatment or whole days off 
work) cycling accidents. The societal costs of accidents in 2011 Australian Dollars 
($) were estimated from self-reported medical resource consumption and lost work 
and leisure time, combined with published medical resource unit costs and sal-
ary data. Results: Participants reported 59 major accidents in 5 years preceding 
the interview, and 27 minor accidents in the previous 12 months. The mean total 
costs per major accident were $12,158, including direct medical costs $2,228, direct 
non-medical costs $372, resulted in 3.7 days off work equating to indirect costs of 
$6,027 and 54.5 days of lost leisure time equivalent to $3,531. The average costs of 
a minor accident were $632 and included direct non-medical costs of $225, pro-
ductivity losses of $117 and 5.2 days of lost leisure time valued at $290. The total 
annual costs to society of major cycling accidents in Tasmania were estimated 
at $4,123,445. cOnclusiOns: Costs resulting from both minor and major cycling 
accidents are substantial. The costs of improvements to cycling infrastructure/safety 
may be offset by reduced costs to society of cycling accidents.
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Objectives: To observe the effect of Iguratimod (T-614) on peripheral blood mon-
onuclear cells (PBMCs),Th1 cells and the expression level of IL-8 of rheumatoid 
arthritis (RA) patients, and to explore the possible mechanism of T-614 in treat-
ing RA. MethOds: 6 patients were diagnosed with RA referred to Department of 
Rheumatology, The Fifth Hospital of Xi’an. They were evaluated by the score of VAS, 
DAS28 and the response rates of ACR20/70, respectively. PBMC were prepared from 
6 patients in active stage of RA. and treated with T-614 at different concentration 
(lower dose: 100ug/ml; Higher dose: 1mg/ml ) for 1h and 24h. Flow cytometry (FCM) 
were performed to examine the apoptosis of PBMC and the level of IFN-γ secre-
tion by T cells. Results: We found that: We found that: 1) Iguratimod effectively 
induced apoptosis in PBMCs in 1h treatment, T-614 100ug/ml was 19.3±2.8% and 
1mg/ml 26.4±3.1%,(P< 0.05); 2) Compared with control, Iguratimod effectively inhibit 
CD3+ T cell secretion at 24h, T-641(1mg/ml) 1.33±0.12% and control (without T-614) 
2.91±0.13% P< 0.05). 3) Levels of IL-8 in the supernatant of T-614 treated group and 
control group were tested by ELISA, Iguratimod effectively inhibit IL-8 prodcution 
and there were significant differences (P< 0.05). cOnclusiOns: The results suggest 
that T-614 induced PBMC apoptosis and decreasing CD3+ T cell IFN-γ production 
and secretion of IL-8 in peripheral blood might be the possible mechanism of the 
effective of T-614 in treatment of RA.
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Objectives: The objective of this pilot study was to assess the barriers to the 
treatment of Osteoporosis in post-menopausal women, from both a physician and 
patient perspective. MethOds: An open-ended structured survey was conducted 
for Physicians and patients across suburban areas of Mumbai. Questionnaires were 
designed to have questions on incidence of fractures, assessment methods for treat-
ment, treatment regimen, for physicians, and history of fractures and compliance 
to treatment for patients, identified thorough review of the literature. Descriptive 
statistics were performed. Results: As Reported by the Physicians ,85% of the post-
menopausal women had vitamin D deficiency, High Incidence of Bone Fracture (hip) 
were common among 70%of Patients, Preferred Regimen was Calcium Supplement 
(Dietary, Oral dose 500mg twice daily), Multivitamins and/or Bisphosphonates 
with Vitamin D (70mg/5,600U tablet Once weekly). Obstacle to treatment were 
Unavailability of Dual energy X-ray absorptiometry (DEXA) Technology which is 
Gold standard for diagnosing osteoporosis was perceived by 80% of physicians to be 
a barrier for Proper diagnosis. Patients advised for DEXA scan were Non-Compliant 
due to Cost of Diagnosis. Time and Cost of Diagnosing and Patient Reluctance were 
reported by Physicians .Major Reason for Non-Compliance were Cost of Therapy 
as Bisphosphonates are costly compared to vitamin D and calcium as it being not 
included under DPCO along with Poor Patient Counselling. cOnclusiOns: The 
survey gives preliminary evidences that Post-Menopausal Women were Vitamin D 
deficient. Unavailability of DEXA for diagnosis was perceived to be a major barrier 
for treatment .Increased cost of therapy and non-compliance could be undertaken 
by Government initiative to consider Bisphosphonates under DPCO and Provide 
DEXA machines in Hospitals for Free scan. Pharmacist can bridge the gap for poor 
Patient Counselling by educating the patient about importance of Adherence to 
Treatment and Occasional DEXA scan to be done for better monitoring of Bone 
loss/Recovery during Regimen.
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Objectives: The prevalence of both lifestyle-related metabolic disorders and 
osteoporosis is increasing in Asia. The aim of this systematic review was to sum-
marise all published studies within Asia on the association between disorders of 
glucose and fat metabolism (type 2 diabetes, hyperglycemia, hypercholesterolemia, 
hyperlipidemia, dyslipidemia, metabolic syndrome (MetS) and atherosclerosis) 
and risk of fracture and osteoporosis. The relationship between metabolic dis-
orders and bone mineral density (BMD) was also examined. MethOds: EMBASE 
(including MEDLINE) and the Cochrane Library were searched. Only studies con-
ducted within Asia (including East, South-East and South Asia and the Middle-
East), which reported multivariate analysis with a sample size ≥ 200 subjects, 
were included. Results: A total of 33 studies were included, of which 32 were 
assessed as adequate and one high quality based on SIGN criteria. All seven studies 
examining diabetes and fracture found that subjects with diabetes had a higher 
risk of fracture compared with subjects without diabetes (risk estimate range: 
1.26 to 4.73). In contrast, no association was found between diabetes and BMD, 
although a high degree of heterogeneity was observed. Two studies found that 
subjects with atherosclerosis had higher risk of fracture (risk estimate range: 
1.10 to 2.52). Included studies consistently reported that MetS is likely associated 
with osteoporosis or decreased BMD in men but not women. There was limited 
evidence investigating lipid metabolism and hyperglycemia and risk of fracture 
or bone loss. cOnclusiOns: These findings suggest that diabetes is a risk factor 
for fracture in Asian populations. Atherosclerosis may also be associated with 
increased fractures in Asian populations, and MetS associated with bone loss in 
